by Amy Berger | Jul 26, 2021 | Blog, News
STARTING OFF ON THE RIGHT FOOT Our inhalation services include preliminary method development activities as the necessary first step for inhalation toxicology studies. The selection and characterization of the test atmosphere to be realistic and extensively measured...
by Amy Berger | Jul 7, 2021 | News, Publications and Press
IITRI is proud to share the promising news from multiple sponsors of COVID-19 in vitro and in vivo studies. Links below to press releases and recent publications. Congrats all! New IITRI Co-Author Publication: Scalable live-attenuated SARS-CoV-2 vaccine...
by Amy Berger | Apr 22, 2021 | Blog, News
IITRI now has access to multiple SARS-CoV-2 variants. Currently available: B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma). Available soon: B.1.617.1 (Kappa) and B.1.617.2 (Delta) These variants are available for use in our assays (immunostain and neutralization) as well...
by Amy Berger | Mar 24, 2021 | Blog
Spread the Word: IITRI has 40+ Years of Experience in GLP Inhalation Studies Many inhalation professionals are unaware that IITRI provides complete end-to-end inhalation toxicology study programs for IND and NDA submissions. We have decades of expertise in aerosol...
by Amy Berger | Jan 27, 2021 | Blog, News
IITRI now offers an improved efficacy assay for looking at effects of drugs on SARS-CoV-2. Although this assay no longer includes a cytotoxicity readout, we offer a neutral red assay in BSl-2 instead if needed. This current assay uses immunostaining and provides more...
Recent Comments